Keywords: Menarini, Oxford BioTherapeutics, Antibody-based cancver drugs

Menarini in $1 billion partnership with Oxford BioTherapeutics for cancer drug development

Article | 29 October 2012

Print This

In a second major deal within just over a year for the UK-based antibody-based drug developer, BioTherapeutics (OBT) has entered ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in